LPA1 Modulation: Admilparant’s Role in the Evolution of IPF and PPF Therapies

Opinion
Video

Eric Cannon, PharmD, FAMCP, discusses how LPA1 receptor activation promotes fibrosis in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) through myofibroblast differentiation and ECM production. Admilparant shows promising antifibrotic activity in preclinical models but requires phase 3 efficacy data. As a novel targeted therapy, it may complement existing antifibrotics, particularly for progressive phenotypes with high LPA1 expression.

Video content above is prompted by the following:

  • What evidence supports the role of LPA1 in modulating fibrotic processes, particularly in IPF and PPF?
  • What has the data demonstrated with admilparant so far, and what future data is needed for this therapy?
  • How do you envision admilparant fitting into treatment algorithms for patients with IPF and PPF?

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos
2 experts are featured in this series.
1 expert is featured in this series.
1 expert in this video
1 expert in this video
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
1 expert in this video
1 expert in this video
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.